Clinical research continues to push boundaries in the treatment and prevention of post-stroke complications. A new trial sponsored by the University Hospital, Clermont-Ferrand is exploring whether combining early neuromodulation with rehabilitation can effectively prevent Central Post Stroke Pain (CPSP). This study is noted as not yet recruiting as of October 2, 2025, and carries significant implications for stroke management.
- What is the study about?
- Why focus on Central Post Stroke Pain?
- Study design and planned interventions
- FAQs
- Implications for stakeholders
- Disclaimer
- Full announcement
What is the study about?
This clinical trial investigates the role of Transcranial Direct Current Stimulation (tDCS) as an early intervention for stroke survivors. Two groups will be assessed: one receiving active tDCS and another undergoing sham (placebo) stimulation. By coupling this neuromodulation technique with rehabilitation therapy, researchers aim to determine its preventive efficacy against CPSP, a common and debilitating consequence of stroke.
Why focus on Central Post Stroke Pain?
CPSP affects a significant number of stroke survivors and can severely impair quality of life. Current treatment options focus on symptom management but do not offer preventative solutions. This study uniquely positions neuromodulation combined with systematic rehabilitation as a proactive approach.
Understanding CPSP
Central Post Stroke Pain stems from neurological damage caused by strokes. It involves chronic neuropathic pain that is resistant to conventional pain relief methods. Devising strategies to mitigate this condition before its onset could revolutionize post-stroke care.
Study design and planned interventions
The trial employs Transcranial Direct Current Stimulation (tDCS), a non-invasive device-based neuromodulation technique. Participants in the active tDCS group will experience low electrical currents targeting specific brain regions, while the sham group undergoes placebo stimulation to ensure methodological rigor.
Device-specific details
Active tDCS devices used in this study aim to promote neuroplasticity and reduce the risk factors associated with CPSP. Device performance, safety, and intended therapeutic outcomes will be closely monitored under MDR compliance standards.
Timeline and recruitment status
As mentioned, the study is not yet recruiting participants. Regular updates will be provided via ClinicalTrials.gov (source) to indicate when enrollment opens.
FAQs
- What makes this study unique?
The integration of neuromodulation and rehabilitation as a preventive strategy sets this apart from other CPSP research. - What is tDCS?
Transcranial Direct Current Stimulation is a non-invasive technique that uses mild electrical currents to influence brain activity. - Who is conducting this trial?
The University Hospital, Clermont-Ferrand is the sponsor. - When can participants enroll?
No definitive timeline is currently available; updates will be posted as the study transitions to active recruitment.
Implications for stakeholders
This innovative clinical trial may offer significant advancements in stroke-related care and the prevention of post-stroke neuropathic pain. Medical device teams should monitor these developments for new opportunities in therapeutic devices. Regulatory and compliance professionals will want to study how neuromodulation therapies fit into evolving MDR frameworks.
Disclaimer
This article is intended for informational purposes for healthcare and regulatory professionals. It does not constitute legal or clinical advice.
Full announcement
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07202455?term=medical+device